Pfizer COVID antiviral: Dozens of companies to start making pill

Nearly three dozen companies in Asia, the Caribbean, the Middle East and Eastern Europe will soon start making either generic versions of Pfizer's coronavirus pill or the raw ingredients. This deal will make the antiviral nirmatrelvir, or Paxlovoid, available to more than half of the world's population.

Which states have lifted mask mandates

With the omicron variant of COVID-19 waning and Americans eager to move beyond the virus, government and business leaders have been out ahead of the CDC in ending virus measures.

The first plant-based Covid vaccine approved in Canada

The decision was based on a study of 24,000 adults that found the vaccine was 71 percent effective at preventing COVID-19 — although that was before the omicron variant emerged. Side effects were mild, including fever and fatigue.